Acumen Pharmaceuticals (ABOS) projects top-line results from its Phase II ALTITUDE-AD trial in late 2026. The company targets an Investigational New Drug (IND) filing in mid-2027 for two EBD candidates.
Q1 2026 Earnings Highlights
During the first quarter, Acumen advanced sabirnetug in the Phase II ALTITUDE-AD trial. This progress builds on clinical momentum gained over the past year, CEO and Director Daniel O’Connell stated in the earnings call.
Pipeline Progress
Acumen continues to prioritize sabirnetug development in Alzheimer’s disease. Officials confirm the trial remains on track, with data readout expected by year-end 2026. Parallel efforts focus on EBD candidates, positioning the company for expanded clinical programs next year.
